Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Smith

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracilMilind M Javle, Shousong Cao, Farukh A Durrani, et al.
The Journal of Infectious Diseases|July 28, 2011
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis CNicole Forestier, Dominique Larrey, Patrick Marcellin, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2013
Population pharmacokinetics of oseltamivir: pediatrics through geriatricsMohamed A Kamal, Scott A Van Wart, Craig R Rayner, et al.
Clinical and Translational Science|November 1, 2021
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)Timothy D Owens, Patrick F Smith, Andrew Redfern, et al.
Ebiomedicine|April 15, 2016
Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A OutbreaksAndrew M Wollacott, Maciej F Boni, Kristy J Szretter, et al.
Pharmacotherapy|September 2, 2004
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadonePatrick F Smith, Brian P Kearney, Sandra Liaw, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith, Gregory K Robbins, Robert W Shafer, et al.
The American Journal of Tropical Medicine and Hygiene|August 24, 2020
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Craig R Rayner, Louis Dron, Jay J H Park, et al.
Plos One|July 19, 2023
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic resultsAbbie Oey, Matthew McClure, Julian A Symons, et al.
Pharmacotherapy|June 26, 2008
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjectsYing-Jun Cao, Patrick F Smith, Mary Beth Wire, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracilMilind M Javle, Shousong Cao, Farukh A Durrani, et al.
The Journal of Infectious Diseases|July 28, 2011
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis CNicole Forestier, Dominique Larrey, Patrick Marcellin, et al.
Antimicrobial Agents and Chemotherapy|May 15, 2013
Population pharmacokinetics of oseltamivir: pediatrics through geriatricsMohamed A Kamal, Scott A Van Wart, Craig R Rayner, et al.
Clinical and Translational Science|November 1, 2021
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)Timothy D Owens, Patrick F Smith, Andrew Redfern, et al.
Ebiomedicine|April 15, 2016
Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A OutbreaksAndrew M Wollacott, Maciej F Boni, Kristy J Szretter, et al.
Pharmacotherapy|September 2, 2004
Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadonePatrick F Smith, Brian P Kearney, Sandra Liaw, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith, Gregory K Robbins, Robert W Shafer, et al.
The American Journal of Tropical Medicine and Hygiene|August 24, 2020
Accelerating Clinical Evaluation of Repurposed Combination Therapies for COVID-19Craig R Rayner, Louis Dron, Jay J H Park, et al.
Plos One|July 19, 2023
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic resultsAbbie Oey, Matthew McClure, Julian A Symons, et al.
Pharmacotherapy|June 26, 2008
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjectsYing-Jun Cao, Patrick F Smith, Mary Beth Wire, et al.
Pageof 7